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ABSTRACT  
Introduction: Acne is a multifactorial and common skin disease which can 
significantly affect the quality of life of sufferers. In this study, a topical herbal 
preparation traditionally used in Ayurvedic medicine was evaluated as a 
treatment for individuals with acne on their shoulders and backs.  
Methods: Study participants were randomly assigned to treatment (Eladi 
Keram) or vehicle control (coconut oil) groups under double blind conditions and 
instructed on its daily home application. Standardised lesion counting and acne 
grading were conducted in accordance with US Food and Drug Administration 
guidelines and with reference to the Leeds Acne Grading Technique. 
Participants were assessed for severity of the condition at commencement and 
on day 28 of treatment.  
Results: The treatment group showed typical improvements of 42% (p<0.005) 
on the Investigators Global Assessment scale, a 60% (p<0.05) reduction in 
inflammatory lesions, a 59% (p<0.05) reduction in non-inflammatory lesions, 
and a 59% (p<0.005) reduction in combined lesion count. The control group 
showed no statistically significant changes for these criteria.  
Conclusion:  This study is the first reported clinical evaluation of Eladi Keram as 
a treatment for acne and findings suggest that it could be effective in reducing 
inflammatory and non-inflammatory lesions, warranting further investigation by 
means of a larger scale clinical trial.  
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1. Introduction 
Acne vulgaris is a common chronic skin disease, predominant in adolescence 
but also affecting a large number of adults [1,2,3]. Although acne is not 
associated directly with mortality or conventionally defined morbidity, the 
discomfort, risk of scarring and often strong emotional distress associated with 
the condition means it is increasingly considered a valid target for treatment 
rather than a condition to be endured [4,5]. Acne is defined by the presence of 
inflamed red papules, pustules, comedones (black or whiteheads) and the 
pathogenesis of the condition involves a complex sequence of events, including 
sebum production, hyperkeratinisation, poral occlusion, colonisation by 
Propionibacterium acnes (P. acnes) bacteria and a persistent inflammatory 
immune response [6]. Microcomedones are often the initial subclinical acne 
lesions which further mature into non-inflammatory comedones and/or 
inflammatory lesions [7,8]. The development of microcomedone is via 
hyperkeratinisation (keratin/infundibular plug) in the follicular infundibulum and 
sebaceous ducts [8]. Follicular epithelial hyperproliferation leads to 
hyperkeratosis and eventually to the formation of microcomedones and this may 
be promoted by increased sebum production.  Hyperkeratosis is characterised 
by increased number and size of keratohyaline granules, lipid droplet 
accumulation, and epidermal scale/keratin flakes [9]. Consequent alteration in 
lipid composition of sebum, bacterial overgrowth, and hormonal factors elicit 
stimulation of the immune and inflammatory responses via the action of CD3+, 
CD4+ (lymphocytes) and macrophages [6,8,9]. The local overproduction of 
androgen hormones including testosterone, dehydroepiandrosterone sulfate, 
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and dihydrotestosterone can regulate sebaceous gland growth and sebum 
production and consequently the formation of acne lesions [7, 9,10,11]. 
Furthermore, androgen is involved in comedogenesis and hyperkeratinisation 
via regulating growth factors and IL-1α [8]. Insulin-like growth factor-1 
production, stimulated by growth hormone, acts on sebaceous glands by 
causing their growth and stimulating lipogenesis [7,8,9]. Under certain 
circumstances, P. acnes, a common commensal Gram-positive anaerobic 
bacterium (usually a benign inhabitant of sebaceous follicles) may act directly or 
indirectly on pilosebaceous ducts and activate certain inflammatory proteins 
(including the pro-inflammatory cytokines) [12] causing inflammation and 
hyperkeratinisation [8]. However, it has also been reported that comedones can 
develop in the absence of P. acnes [13].  
A range of conventional treatments for acne exist including oral and topical 
retinoids, antibiotics, benzoyl peroxide and hormonal treatments [14], but 
concerns over side effects of retinoids including severe depression [15] and the 
development of antibiotic resistance to P. acnes [16] have created an appetite 
for novel treatments, including the use of herbal preparations [17,18]. 
 
Eladi Keram is a commercially available Ayurvedic herbal formulation with a 
long standing anecdotal evidence base as an effective treatment for various 
skin conditions including acne (referred in classical Ayurvedic text as “pidaka” a 
form of Kushta (skin disease)) [19,20]. The fact that this ancient formula (Eladi 
Keram) is still widely manufactured and prescribed by Ayurvedic practitioners, 
highlights the cultural importance of these formulations to the rich 
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ethnopharmacological tradition of Indian medicine. Although Eladi Keram has a 
long standing anecdotal evidence base as an effective treatment for various 
skin conditions, prior to this study, there has been no reported clinical 
evaluation using a biomedical model of research. It is on this basis together with 
interest in novel treatments and potential reduced side effects of herbal 
remedies that Eladi Keram was deemed worthy of investigation 
 
2. Materials and methods 
2.1. Study design and study groups 
A randomised controlled pilot study was conducted to evaluate the 
effectiveness of Eladi Keram for participants with acne on their shoulders and 
backs in a double-blinded clinical observation. Eladi Keram was selected for the 
study because it met our selection criteria of being a commercially available 
traditional medicine with long-standing use, and with claims of efficacy by 
traditional medicine practitioners and users. The study deliberately focused on 
subjects with acne on the shoulders and backs rather than on the face. 
Although greater emotional distress is associated with facial acne [3] and 
therefore its targeting may be more beneficial, this is countered by the greater 
likelihood of participants self-treating and/or masking facial acne during the trial. 
This would lead to the increased possibility of introducing confounding variables 
in such subjects suggesting that a study on back and shoulder acne would in 
practice be more scientifically robust. Moreover, any potential benefits noted in 
the treatment of back and shoulder acne are also likely to be relevant to 
subjects with facial acne.  
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There is a higher prevalence of acne in 15 – 24 year olds but some older people   
have been confirmed as sufferers as evidenced by UK GP returns analysis [21]. 
In this study, under 18 year olds were excluded from the study due to ethical 
and recruitment issues. The present clinical observation study was conducted 
on participants, aged 19 - 50 (mean = 30.05 and median = 30), reporting acne 
on shoulders or chest unless they reported the following exclusion criteria: 
being pregnant, breast feeding, taking other medication for acne, using sun 
tanning lamps/planning travel to sunny climates, or reporting shellfish allergy. A 
power calculation (see Statistical Analysis) indicated that approximately 20 
participants were required to demonstrate a statistically significant and clinically 
meaningful reduction in acne. From 24 enquiries, three recruits did not fulfil the 
inclusion criteria. A total of 21 participants (6 male and 15 female) therefore 
were enrolled. Ten were randomly (using Minitab ® statistical software random 
data sampling function (Minitab Ltd. Coventry, U.K.)) assigned to the treatment 
group and eleven to the control group.  
 
Ethical approval was granted by Middlesex University Ethics Natural Sciences 
Sub-Committee and written informed consent was obtained from each 
participant prior to study commencement.  
 
2.2. Test samples  
Eladi Keram was purchased from Nagarjuna Ayurvedic Group 
(http://www.nagarjunaayurveda.com/) and the constituent herbs were 
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authenticated by the manufacturers using thin layer chromatography 
fingerprinting according to the Indian Government Good Manufacturing 
Practice. Eladi Keram contains 27 dried herbal ingredients (Table 1) prepared in 
coconut oil (Cocos nucifera) as detailed in Ayurvedic texts including Nishteswar 
and Vidyanath [19] and Sharma [20]. Except for trace amounts of oyster shell, 
Eladi Keram does not contain any animal ingredients, nor herbs threatened with 
extinction as listed in the International Union for Conservation of Nature 
(I.U.C.N.) Red Data List of Medicinal Plants. Coconut was used as the control 
skin agent and the oil was purchased from KTC Wednesbury, England.  
 
The treatment and control test samples (200 mL) were placed in plain 
polyethylene cosmetic bottles (Ampulla U.K. Limited, Hyde, Cheshire) labelled 
once and randomly (using Minitab ® random data sampling function) re-labelled 
in the primary investigator’s absence by a trusted third party. Thus, neither 
participant nor researcher was aware of the identity of the treatment 
administered. Unblinding took place after trial completion and results 
collation/analysis, thus triple-blinding the study.  
 
2.3. Assessment of the effect of Eladi Keram and coconut oil on acne 
Participants attended enrolment consultations where they were assessed and 
provided written consent prior to being given a patch test and being shown how 
to apply the topical medication, either the treatment formulation (Eladi Keram) 
or the vehicle control (coconut oil). Briefly, participants were instructed to place 
the container in warm water to liquefy the contents prior to shaking the bottle 
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gently and then applying approximately 5 mL to the affected areas once a day. 
They were also instructed not to apply any other product during the study. 
 
Clinical assessment was undertaken according to the Investigator’s Static 
Global Assessment Scale (IGA scale), recommended by the US Food and Drug 
Administration [22]. Grades were recorded, alongside lesion counts 
documenting inflammatory and non-inflammatory lesions as separate 
categories on an anonymous record sheet coded with participant identifier 
number. Photographs were taken of each participant’s back and shoulders for 
an ancillary visual record. The IGA scale builds on grading systems originating 
in the seminal research of Burke and Cunliffe [23]. Using this scale, 0 is the 
absence of lesions and 4 indicates the most severe condition. Reduction to 1 or 
0 can be viewed as a successful treatment, as can a 2-point reduction in 
severity which was also deemed as a clinically meaningful effect size for sample 
determination (Section 2.4). 
 
On day 28 day of self-treatment, participants returned for debriefing and 
assessment. Nineteen of the 21 participants returned for follow up. Five 
participants elected to continue with treatment and were monitored beyond 28 
days. These participants were requested to return on day 56 for assessment. 
This allowed longer range data to be collected which are also reported herein. 
 
2.4. Statistical Analysis 
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Statistical analyses were performed using Minitab® statistical software.  Sample 
size was determined using a power calculation on the basis that a 2-point 
reduction on the IGA scale was considered a clinically meaningful effect size. A 
conventional approach of a 4:1 ratio of β:α risk was employed and therefore a 
power value of 0.8 and a significance value of 0.05 together with a conservative 
a priori assumption of an anticipated standard deviation of 1.5 points in the 
sample IGA scores were used for the sample size calculation. Using these 
parameters, a sample size of 10 in each group achieved a power of 0.805.  
Significance of shifts within control and treatment groups from day 0 - day 28 
(and thence for some subjects to day 56) were analysed using paired two-tailed 
t tests. Comparisons of these shifts between treatment and control group were 
conducted using two sample (independent) t tests. Assumptions of homogeneity 
of variance and underlying normality of distributions were tested using standard 
equal variance testing and the Anderson-Darling normality test as appropriate. 
Ordinal data (IGA scale) was analysed using the Mann–Whitney U test. 
Comparisons to other studies (where raw measurements could not be directly 
compared) were made using Cohen’s-d measure. 
 
3. Results  
3.1. The effect of Eladi Keram and coconut oil on acne 
Summarised results for inflammatory lesion counts, non-inflammatory lesion 
counts, combined lesion counts and the IGA scale for the control (n=11) and 
treatment (n=10) groups are presented in Fig. 1.  The 95% confidence intervals 
for the mean shifts in lesion counts and IGA scale measures in the treatment 
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group strongly suggest significant improvements in this group. In contrast, the 
lesion count and IGA measures show insufficient evidence of any improvement 
in the control group, with some measures indicating a small deterioration in skin 
condition. 
 
 
The mean changes observed at 28 days were directly compared for the 
treatment group versus the control group for the three lesion counts using 
independent two sample t tests. Inflammatory lesion count showed a mean 
improvement of -8 (p=0.037); non-inflammatory lesion count an improvement of 
-16 (p=0.011) and the combined lesion count gave an improvement of -24 
(p=0.003). IGA changes were subjected to the Mann-Whitney U test which 
showed a median shift of 1 scale grade unit (p=0.007). These results 
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summarised in Fig. 1 show the significant improvement made in the treatment 
group compared to the control group across the four assessed parameters. 
None of the four effect measures yielded significant results in the control group. 
Two participants did not complete the trial and stated that they had abandoned 
treatment due to a lack of improvement in their condition.  Under standard 
protocol these subjects were recorded as having static results unchanged after 
treatment. Unblinding revealed both were in the control group, an outcome 
which was concomitant with the control group results as well as the overall 
study findings. 
Five participants in the treatment group opted to continue with treatment on an 
open label basis. After 56 days, these participants continued to improve, with 
three criteria yielding further statistically significant mean improvements 
compared to the 28 days results: non-inflammatory lesion count -25 (p=0.033); 
combined lesion count -31 (p=0.045); IGA score -1 (p=0.033). The exception 
was the inflammatory lesion count change which had a non-statistically 
significant improvement of -6 (p=0.178). No adverse reactions were reported by 
any participant suggesting that a future larger scale study could consider longer 
treatment duration.  
 
3.2. Review of the anti-bacterial and anti-inflammatory effect of constituents of 
Eladi Keram from the literature   
Eladi Keram contains 27 herbs; 15 have been reported to possess antibacterial 
properties and 22 to have anti-inflammatory properties. Eleven herbs are 
reputed to possess both antibacterial and anti-inflammatory properties.  
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3. Discussion   
Eladi Keram appears to have a slow but sustained effect on changing the 
character of acne-troubled skin. There are no reported negative systemic, 
irritating or drying side effects of Eladi Keram in this study or in the published 
literature. Therefore, Eladi Keram may be suitable for long term use over 
several months. In general, inflammatory lesions are often more established 
than non-inflammatory comedones (white heads and black heads). Recovery 
from chronic inflammatory lesions takes longer and may result in physical 
changes to the skin, such as scarring. In contrast, comedones are characterised 
by occluded pores which can respond positively to treatment within shorter 
timescales [6]. Nevertheless, in this study Eladi Keram showed comparable 
improvement in non-inflammatory and inflammatory lesion counts. Thus 
increasing treatment duration could demonstrate a greater treatment benefit of 
Eladi Keram in future studies. 
 
No scientific studies on Eladi Keram for acne have been published to date. 
However, it is worthwhile comparing the findings of this study to those of clinical 
trials which have used different topical preparations for a similar amount of time. 
To this end, a Cohen’s d comparison was made between the effect sizes 
observed from this trial and that conducted by Parveen et al. [68] who 
undertook a controlled randomised trial of a traditional topical Unani herbo-
mineral preparation (treatment group n=20). At 30 days the improvement effect 
size achieved could be expressed as Cohen’s d = 1.11 (0.93, 1.29 [95% 
confidence interval]) where the effect size is equivalent to 1.11 standard 
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deviations. In the currently reported study, the effect size after 28 days could be 
expressed as Cohen’s d = 1.72 (1.4, 2.15) (treatment group n=10). Thus, based 
on Cohen’s d comparison, the currently reported treatment with Eladi Keram 
was 55% more beneficial than another traditional herbo-mineral formula when 
used for a similar duration. 
 
In comparison to treatment with proprietary topical pharmaceutical preparations 
used in combination therapy, the effectiveness of Eladi Keram is weaker. Wolf 
et al. [69] conducted a controlled trial of a topical combination therapy (antibiotic 
clindamycin and topical retinoid adapalene) compared with base cream 
(n=125). Their study produced an improvement in inflammatory lesion count of 
11.4 (p<0.005) after 28 days treatment. This compares with an improvement of 
8 (p<0.05) for Eladi Keram. One could state that combination therapy with 
retinoid and antibiotic cream was 53% more effective in treating acne when 
compared to Eladi Keram. The reduced impact of Eladi Keram when compared 
with conventional treatment can be explained by the assumption that treatment 
with polyherbal formulations using whole plant extracts at low concentrations 
will be less pronounced in the short term and may take longer to display positive 
treatment effects. Further studies are required to evaluate the dose-dependent 
effect of Eladi Keram by altering the concentrations of the herbal constituents to 
determine the optimal compositions, in consultations with Ayuverdic 
practitioners.  The currently reported study yielded no adverse reactions, 
whereas the pharmaceutical study reported two adverse events namely, 
dryness and stinging/burning [69]. In addition, given issues of antibiotic 
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resistance and known negative side effects of some acne treatments, a mild 
alternative may suit some patients. On this basis, comparison of the speed of 
improvement observed under the apparently milder action of Eladi Keram is not 
unfavourable. In this trial, treatment was restricted to 28 days with the aim of 
increasing compliance and reducing drop outs. 
 
Several factors, including bacterial infection by P. acnes contribute to the 
development of acne. However, P. acnes is no longer believed to be the cause 
of acne and the role of this bacterium in the pathogenesis of acne is still unclear 
[12]. Fifteen of the constituent herbs of Eladi Keram have been reported to exert 
an antibacterial effect against different strains of bacteria (Table 1). However, 
there are only two reports on the inhibitory action of herbs in Eladi Keram 
against P. acnes namely Cinnamomum zeylanicum (in the form of an essential 
oil) [36] and Ipomoea pes-tigridis (compounds in the methanolic extract) [49]. 
Although the anti-bacterial action of Eladi Keram against P. acnes specifically 
has not been demonstrated, other potential modes of action exist including anti-
inflammatory activity. The process of acne lesion formation is initiated by 
various immune changes and inflammatory responses [6,8]. Twenty-two (out of 
27) constituents of Eladi Keram exert anti-inflammatory effects (Table 1) via 
different mechanisms.  For example, Tsai et al. [30] reported that Calophyllum 
inophyllum significantly inhibits the expression of proinflammatory proteins, 
including the transcriptional factor, nuclear factor-kappaB (NF-κB), 
cyclooxygenase-2 and inducible nitric oxide (enzymes involved in the production 
of prostaglandin E2 and nitric oxide, respectively). C. zeylanicum is also 
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reported to exert anti-inflammatory effects (both in vivo and in vitro) through the 
inhibition of tumour necrosis factor-α (TNF-α) [38]. Eladi Keram may therefore 
inhibit pro-inflammatory proteins, thus reducing inflammation, but this effect has 
yet to be tested.  Another potential pathway is a keratolytic effect on hardened 
pore openings to reduce poral occlusion. Coconut oil (the base oil for the 
formula) is known generally as an emollient which helps to prevent the 
epidermis drying, making the skin better able to retain water [70]. This quality 
may help to prevent poral occlusion and would apply equally to both the control 
and treatment groups in this study. This could explain the reason some 
participants in the control group experienced a reduction in non-inflammatory 
lesion count after treatment with coconut oil, but given the significant 
improvement in the treatment group this mechanism clearly cannot wholly 
explain Eladi Keram’s mode of action. Antiseborrhoeic action (reducing excess 
sebum production) is a further potential pathway that may explain the efficacy of 
Eladi Keram. Sebaceous glands have been shown to control endocrine and 
immune type functions within the skin and have both direct and indirect 
antibacterial functions. Sebum contains an antimicrobial lipid (sapienic acid), 
which increases in response to skin bacterial presence [6,9]. Excessive sebum 
production provides an anaerobic growth setting for P. acnes in part due to its 
lipid content, and produces lipases which hydrolyse triglycerides into pro-
inflammatory free fatty acids [8]. Macrophages surrounding the pilosebaceous 
follicles are presented with Toll-like receptors (TLRs), a subtype of pattern 
recognition receptors [7]. TLR-2 and TLR-4 are specific for acne pathogenesis 
and they can be stimulated by P. acnes ligation [8]. Activated TLR induces NF-
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κB thus promoting the transcription of chemokines and adhesion molecules and 
lead to increased production of the cytokines, IL-1, IL-6, IL-8, IL-10, IL-12, and 
TNF-α, triggering an inflammatory response in acne patients which presents as 
visible inflammatory lesions [7,8,9]. The sebaceous glands also work as 
localised independent endocrine organs responding to hormones, as well as 
being involved in neurological signalling and immune type responses. This has 
an important role in responding to stress and maintaining normal functioning 
[6,9]. This suggests control of sebocytes’ function and maintenance of 
homeostatic functioning would support a reduction in excess inflammatory 
response and excess sebum production, phenomena observed in the formation 
of papules and pustules. The highlighted role of sebocytes indicates that Eladi 
Keram may therefore act through an anti-seborrhoeic route, a pathway more 
significant than previously considered, as it may support localised regulation of 
endocrine and inflammatory signalling and responses. Although we suspect that 
this proposed mode of action is important we cannot directly link the observed 
biological effect with any known constituent of Eladi Keram. This highlights the 
need for further investigation into the precise mode of action, including 
synergistic effects of herbs contained in herbal treatments such as Eladi Keram.  
 
4. Conclusion 
This study is the first reported clinical evaluation of Eladi Keram’s effectiveness 
in treating acne. We were able to show a clinically meaningful and statistically 
significant improvement of upper body Acne vulgaris under randomised and 
double blinded conditions. Given the relatively small sample size employed, 
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caution should be exercised in extrapolating the findings to a wider population 
or in extrapolating the findings to the treatment of the more distressing condition 
of facial acne. Nevertheless, this small-scale study has generated extremely 
promising data on the efficacy of Eladi Keram. The absence of any participant 
adverse reaction and the elected continued participation and improvement in 
some individuals beyond the initial study duration suggest that Eladi Keram may 
be safely tested for acne treatment. The overall findings warrant further 
investigation into the mode of action of Eladi Keram and importantly suggest 
that an extended and larger clinical trial involving facial acne treatment may 
yield significant findings.   
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